Assertion: lymphoma's treatment | /r/CapableOf | show promising with progression-free survival
Facets:
value: in 2006
type: TEMPORAL
Source sentences:
text: In 2006, treatment with dose-adjusted EPOCH with Rituximab showed promising initial results in a small series of patients (n=17), with a 100% response rate, and 100% overall survival and progression-free survival at 28 months (median follow-up).